Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data
- PMID: 22541275
- PMCID: PMC3918517
- DOI: 10.1016/S0140-6736(12)60441-3
Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data
Erratum in
- Lancet. 2012 Aug 4;380(9840):474
Abstract
Background: Carotid intima-media thickness (cIMT) is related to the risk of cardiovascular events in the general population. An association between changes in cIMT and cardiovascular risk is frequently assumed but has rarely been reported. Our aim was to test this association.
Methods: We identified general population studies that assessed cIMT at least twice and followed up participants for myocardial infarction, stroke, or death. The study teams collaborated in an individual participant data meta-analysis. Excluding individuals with previous myocardial infarction or stroke, we assessed the association between cIMT progression and the risk of cardiovascular events (myocardial infarction, stroke, vascular death, or a combination of these) for each study with Cox regression. The log hazard ratios (HRs) per SD difference were pooled by random effects meta-analysis.
Findings: Of 21 eligible studies, 16 with 36,984 participants were included. During a mean follow-up of 7·0 years, 1519 myocardial infarctions, 1339 strokes, and 2028 combined endpoints (myocardial infarction, stroke, vascular death) occurred. Yearly cIMT progression was derived from two ultrasound visits 2-7 years (median 4 years) apart. For mean common carotid artery intima-media thickness progression, the overall HR of the combined endpoint was 0·97 (95% CI 0·94-1·00) when adjusted for age, sex, and mean common carotid artery intima-media thickness, and 0·98 (0·95-1·01) when also adjusted for vascular risk factors. Although we detected no associations with cIMT progression in sensitivity analyses, the mean cIMT of the two ultrasound scans was positively and robustly associated with cardiovascular risk (HR for the combined endpoint 1·16, 95% CI 1·10-1·22, adjusted for age, sex, mean common carotid artery intima-media thickness progression, and vascular risk factors). In three studies including 3439 participants who had four ultrasound scans, cIMT progression did not correlate between occassions (reproducibility correlations between r=-0·06 and r=-0·02).
Interpretation: The association between cIMT progression assessed from two ultrasound scans and cardiovascular risk in the general population remains unproven. No conclusion can be derived for the use of cIMT progression as a surrogate in clinical trials.
Funding: Deutsche Forschungsgemeinschaft.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Michiel Bots has received grants from AstraZeneca, Dutch Heart Foundation, Organon, Pfizer, Servier, the Netherlands Organisation for Health Research and Development, and TNO-Zeist, and consultancy fees from AstraZeneca, Boeringher, Organon, Pfizer, Servier, Schering-Plough, and Unilever. He runs the Vascular Imaging Center in Utrecht, a core laboratory for cIMT measurements in national and international observational and intervention studies. All other authors declare that they have no conflicts of interest.
Figures
Comment in
-
Carotid intima-media thickness and cardiovascular events.Lancet. 2012 Jun 2;379(9831):2028-30. doi: 10.1016/S0140-6736(12)60652-7. Epub 2012 Apr 27. Lancet. 2012. PMID: 22541276 No abstract available.
-
Risk factors: Is measurement of change in cIMT useful?Nat Rev Cardiol. 2012 May 15;9(7):376. doi: 10.1038/nrcardio.2012.73. Nat Rev Cardiol. 2012. PMID: 22584942 No abstract available.
-
[Does an increasing intima media thickness predict the cardiovascular risk? - A non evidence-based procedure does not reveal clinical significant results].Dtsch Med Wochenschr. 2012 Sep;137(36):1732. doi: 10.1055/s-0032-1326799. Epub 2012 Aug 29. Dtsch Med Wochenschr. 2012. PMID: 22933192 German. No abstract available.
Similar articles
-
Varying Definitions of Carotid Intima-Media Thickness and Future Cardiovascular Disease: A Systematic Review and Meta-Analysis.J Am Heart Assoc. 2023 Dec 5;12(23):e031217. doi: 10.1161/JAHA.123.031217. Epub 2023 Nov 28. J Am Heart Assoc. 2023. PMID: 38014663 Free PMC article.
-
Common carotid intima-media thickness relates to cardiovascular events in adults aged <45 years.Hypertension. 2015 Apr;65(4):707-13. doi: 10.1161/HYPERTENSIONAHA.114.04658. Epub 2015 Jan 26. Hypertension. 2015. PMID: 25624341
-
Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration.PLoS One. 2018 Apr 12;13(4):e0191172. doi: 10.1371/journal.pone.0191172. eCollection 2018. PLoS One. 2018. PMID: 29649236 Free PMC article.
-
Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration.Diabetes Care. 2015 Oct;38(10):1921-9. doi: 10.2337/dc14-2732. Epub 2015 Jul 15. Diabetes Care. 2015. PMID: 26180107 Free PMC article. Review.
-
Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis.Atherosclerosis. 2013 May;228(1):1-11. doi: 10.1016/j.atherosclerosis.2013.01.025. Epub 2013 Jan 25. Atherosclerosis. 2013. PMID: 23395523 Review.
Cited by
-
The Potential of Neuregulin 4 as a Novel Biomarker and Therapeutic Agent for Vascular Complications in Type 2 Diabetes Mellitus.J Inflamm Res. 2024 Nov 9;17:8543-8554. doi: 10.2147/JIR.S492115. eCollection 2024. J Inflamm Res. 2024. PMID: 39539725 Free PMC article. Review.
-
Plasma proteomics and carotid intima-media thickness in the UK biobank cohort.Front Cardiovasc Med. 2024 Oct 2;11:1478600. doi: 10.3389/fcvm.2024.1478600. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39416432 Free PMC article.
-
Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial.Cardiovasc Diabetol. 2024 Oct 14;23(1):361. doi: 10.1186/s12933-024-02451-4. Cardiovasc Diabetol. 2024. PMID: 39402581 Free PMC article. Clinical Trial.
-
Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology.Ital J Pediatr. 2024 Oct 8;50(1):205. doi: 10.1186/s13052-024-01767-x. Ital J Pediatr. 2024. PMID: 39380079 Free PMC article. Review.
-
2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.Acta Cardiol Sin. 2024 Sep;40(5):479-543. doi: 10.6515/ACS.202409_40(5).20240724A. Acta Cardiol Sin. 2024. PMID: 39308649 Free PMC article.
References
-
- Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459–67. - PubMed
-
- Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22. - PubMed
-
- Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603–38. - PubMed
-
- Yamasaki Y, Katakami N, Furukado S, et al. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb. 2010;17:1132–40. - PubMed
Publication types
MeSH terms
Grants and funding
- HHSN268201100012C/HL/NHLBI NIH HHS/United States
- HHSN268201100009I/HL/NHLBI NIH HHS/United States
- HHSN268201100010C/HL/NHLBI NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- HHSN268201200036C/HL/NHLBI NIH HHS/United States
- RG/08/014/24067/BHF_/British Heart Foundation/United Kingdom
- R01 HL080295/HL/NHLBI NIH HHS/United States
- HL080295/HL/NHLBI NIH HHS/United States
- R01 AG015928/AG/NIA NIH HHS/United States
- HHSN268201100008C/HL/NHLBI NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- MC_U105260792/MRC_/Medical Research Council/United Kingdom
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- HHSN268201100008I/HL/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- R01 DE013094/DE/NIDCR NIH HHS/United States
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- HHSN268200800007C/HL/NHLBI NIH HHS/United States
- N01 HC015103/HC/NHLBI NIH HHS/United States
- R56 AG020098/AG/NIA NIH HHS/United States
- N01 CN015103/CN/NCI NIH HHS/United States
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- N01 HC085085/HC/NHLBI NIH HHS/United States
- AG-20098/AG/NIA NIH HHS/United States
- N01HC55222/HL/NHLBI NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- N01HC85086/HL/NHLBI NIH HHS/United States
- R37 NS029993/NS/NINDS NIH HHS/United States
- AG-027058/AG/NIA NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- N01 HC-55222/HC/NHLBI NIH HHS/United States
- R37 NS 029993/NS/NINDS NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01-HC-75150/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- N01 HC085084/HC/NHLBI NIH HHS/United States
- R01 AG020098/AG/NIA NIH HHS/United States
- N01HC85082/HL/NHLBI NIH HHS/United States
- N01HC75150/HL/NHLBI NIH HHS/United States
- HHSN268201100009C/HL/NHLBI NIH HHS/United States
- N01HC85083/HL/NHLBI NIH HHS/United States
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
- N01-HC-85079/HC/NHLBI NIH HHS/United States
- N01-HC-85239/HC/NHLBI NIH HHS/United States
- AG-023629/AG/NIA NIH HHS/United States
- N01HC85079/HL/NHLBI NIH HHS/United States
- R01 AG023629/AG/NIA NIH HHS/United States
- R01 AG027058/AG/NIA NIH HHS/United States
- N01 HC045133/HC/NHLBI NIH HHS/United States
- N01HC85080/HL/NHLBI NIH HHS/United States
- N01 HC035129/HC/NHLBI NIH HHS/United States
- R56 AG023629/AG/NIA NIH HHS/United States
- N01HC85081/HL/NHLBI NIH HHS/United States
- R01 DE 13094/DE/NIDCR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
